BRIEF—Orphazyme partners with Centogene on Gaucher trial

More and more drug developers turn to organizations with large genetic datasets and patient information to speed up and increase the success rate of their trials.

Today, Danish Orphazyme chose German company Centogene for a clinical development collaboration in neuronopathic Gaucher disease, a rare, inherited, progressive and debilitating lysosomal storage disorder.

Under the terms of the agreement, Centogene is supporting Orphazyme’s clinical trial efforts in India for the use of arimoclomol for the treatment of neuronopathic Gaucher disease.

Orphazyme acquired right to arimoclomol from CytRx in 2011 in a deal worth up to $120 million to the latter and included two other compounds, iroxanadine and bimoclomol

Centogene is responsible for processing and analyzing a variety of different sample types from patients participating in the trial including plasma, cerebral spinal fluid and dried blood spots from Centogene’s CentoCard.

Furthermore, Centogene has developed and is using the most sensitive and validated biomarker for Gaucher disease, lysoGb1, as a monitoring tool during the trial.